HEPA - Hepion pharmaceuticals announces positive data for NASH treatment CRV431

Hepion Pharmaceuticals  (HEPA) announces data from its low dose cohort in its Phase 2a ‘AMBITION' clinical trial of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis.This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.The AMBITION trial is a placebo-controlled study of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis. In this study, which is being conducted at 10 U.S. sites, 75 mg CRV431 (low dose) was administered orally, once-daily for 28 days.The primary objectives of the AMBITION trial are to assess safety and tolerability of CRV431, as well as to delineate pharmacokinetics (("PK")).The secondary outcome measure of this Phase 2a trial is to evaluate decreases in antifibrotic markers from baseline to the end of study. Phase 2b trial is anticipated to start midway through 2021.The results of the low dose group indicated that CRV431 was generally

For further details see:

Hepion pharmaceuticals announces positive data for NASH treatment CRV431